VNS Therapy System
LivaNova USA, Inc. · Decision date Sep 5, 2025
What did the FDA approve?
FDA records P970003/S248 as a supplement to PMA P970003, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 5, 2025.
FDA approval order statement
Approval for:1. VNS Therapy Epilepsy Physicians Manuals:Update to create a new Management of Depression as a Comorbidity section to inform physicians that depression is a common comorbidity for epilepsy patients and to follow standard medical practice for follow up with these patients and monitoring of their depressive symptoms. Document 26-0011-0100 (Epilepsy Manual; Appendix 1, page 117) New Section added to the Post-Implant Management Chapter: Follow-up Visits: Long-Term Follow Up Section- 7.1.2.2.1 Management of Depression as a Comorbidity:Depression is a common comorbidity in patients with epilepsy. In accordance with standard medical practice, patients with a current or prior diagnosis of depression should be advised to report any new or worsening depressive symptoms, including suicidal ideation.2. VNS Therapy Epilepsy Patient Guide:Update to create a new Patients with Depression section to inform patients that may also have depression to follow up with their doctor if they have new or worsening depressive symptoms. Document 26-0011-1600 (Epilepsy Patient Guide; Appendix 2, page 19). New section added to the Follow Up After Surgery Chapter: After Treatment Begins Section- 6.4.3 Patients with Depression:Some people with epilepsy also have depression. If you have depression now or had it in the past, it is important to monitor your mood and mental health. Contact your doctor if you notice any new or worsening depressive symptoms, including suicidal thoughts.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Neurology
- Decision date
- Sep 5, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P970003/S248
- Regulatory pathway
- PMA supplement
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- Decision code
- APPR
- Decision date
- Sep 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970003 · Original PMA
VNS THERAPY SYSTEM
P970003/S248 received
Application receipt date recorded by FDA.
P970003/S248 · FDA decision
Special (Immediate Track)
P970003/S250 · Related supplement
VNS Therapy System
P970003/S251 · Related supplement
VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand
P970003/S252 · Related supplement
VNS THERAPY SYSTEM
P970003/S253 · Related supplement
VNS Therapy System
P970003/S249 · Related supplement
VNS Therapy System
P970003/S254 · Related supplement
VNS Therapy System
Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VNS THERAPY SYSTEMP970003 | LivaNova USA, Inc. | PMA approval | Jul 16, 1997 | FDA |
VNS Therapy SystemP970003/S250 | LivaNova USA, Inc. | PMA supplement | Sep 12, 2025 | FDA |
| LivaNova USA, Inc. | PMA supplement | Nov 25, 2025 | FDA | |
VNS THERAPY SYSTEMP970003/S252 | LivaNova USA, Inc. | PMA supplement | Dec 17, 2025 | FDA |
VNS Therapy SystemP970003/S253 | LivaNova USA, Inc. | PMA supplement | Mar 4, 2026 | FDA |
VNS Therapy SystemP970003/S249 | LivaNova USA, Inc. | PMA supplement | Aug 12, 2026 | FDA |
VNS Therapy SystemP970003/S254 | LivaNova USA, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LivaNova USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Cyberonics Blvd., Houston, TX, 77058
Sources and methodology
- Original FDA record: P970003/S248
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



